Vertex Pharmaceuticals (VRTX) reported Q1 non-GAAP earnings late Monday of $4.06 per diluted share, down from $4.76 a year earlier.
Analysts polled by FactSet expected $4.25.
Revenue for the quarter ended March 31 was $2.77 billion, up from $2.69 billion a year earlier.
Analysts surveyed by FactSet expected $2.86 billion.
The company adjusted its full-year 2025 revenue guidance to $11.85 billion to $12 billion from $11.75 billion to $12 billion earlier. Analysts expect $11.99 billion.
Shares of Vertex were down 3% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.